Volibo R 0.3/1 mg (Voglibose + Repaglinide) – Post-Meal Blood Sugar Control Treatment

Volibo R 0.3/1 mg is an antidiabetic medicine. It contains Voglibose and Repaglinide as the active ingredients. It is prescribed for the treatment of Type 2 diabetes mellitus. Repaglinide causes an increase in the amount of insulin produced by the pancreas by stimulating the pancreas to release insulin to your body. It helps regulate the amount of sugar in the bloodstream.

Voglibose helps control blood sugar levels by inhibiting the alpha-glucosidase intestinal enzyme and delaying the digestion and absorption of carbohydrates in the intestines. Together they work to prevent a sudden blood sugar hike after meals. The antidiabetic agent is often used in combination with diet and exercise to treat type 2 diabetes mellitus in patients to help control blood sugar levels.

Precautions

Volibo R is not recommended for people with people who are hypersensitive to Repaglinide or Voglibose. The antidiabetic agent may also contain inactive ingredients that cause allergic reactions or other problems. Before you take Volibo R, inform your doctor if you have been asked to undergo major surgery or have severe illness trauma, chronic intestinal disease, infection, fever, or kidney disease such as mild to moderate, severe renal impairment. During pregnancy/lactation, this antidiabetic agent should only be used when medically required and advised.

Dosage Instructions

Side Effects

Some people may experience common side effects such as hypoglycemia, diarrhea, heartburn, stomach pain, nausea, and vomiting. Most of these side effects do not require medical help and will resolve gradually. However, you are advised to speak to your doctor if you develop side effects persistently.

How to Use

How to use

Take Volibo R orally before or after consuming food as directed by the doctor, usually once daily in the morning. Swallow the pill with water without breaking, chewing, or crushing the pill. The dosage is based on the medical condition and response to treatment. Use this medicine regularly to get the most benefit from it. To help you remember, take it at the same time each day.

Let your doctor know if your condition does not worsen (your blood sugar becomes too low or too high). Do not stop treatment even if you feel better, as your blood glucose level keeps changing. If you stop taking Volibo R abruptly, it may increase your blood sugar levels which could further increase the risk of vision loss, severe kidney disease, and nerve damage. Volibo R should not be taken if you have type 1 diabetes mellitus or severe liver or kidney disease.

Infographics

FAQ

What is Volibo R 0.3/1mg and what condition does it treat?

Volibo R 0.3/1mg is a combination antidiabetic medication containing voglibose and repaglinide as active ingredients. This dual-action diabetes medicine is specifically prescribed to manage type 2 diabetes mellitus in adults. Voglibose works as an alpha-glucosidase inhibitor to control post-meal blood sugar spikes, while repaglinide acts as a meglitinide to stimulate insulin release from the pancreas. Together, these components provide comprehensive glycemic control by addressing both fasting and postprandial glucose levels. This combination therapy is particularly beneficial for patients whose blood sugar remains inadequately controlled with single-agent treatment alone.

How does Volibo R 0.3/1mg work to control blood sugar levels?

Volibo R 0.3/1mg employs a dual mechanism to regulate blood glucose. Voglibose inhibits alpha-glucosidase enzymes in the small intestine, slowing carbohydrate breakdown and delaying glucose absorption after meals. This reduces post-meal sugar spikes significantly. Repaglinide stimulates pancreatic beta cells to release insulin quickly in response to meals, lowering blood glucose when it rises. This meglitinide component acts rapidly but briefly, mimicking the body's natural insulin response. Together, these complementary actions provide balanced diabetes management throughout the day, addressing both immediate post-meal glucose elevation and overall glycemic control without causing prolonged hypoglycemia risk.

How quickly does Volibo R 0.3/1mg start working after taking it?

Volibo R 0.3/1mg begins working within 15 to 30 minutes after ingestion, with repaglinide acting particularly fast to stimulate insulin secretion. Peak blood concentration occurs approximately one hour after administration, making it effective for controlling post-meal glucose surges. The voglibose component starts inhibiting carbohydrate digestion immediately upon reaching the intestines. While individual response times vary, most patients notice improved postprandial blood sugar readings within the first few doses. However, achieving optimal long-term glycemic control typically requires consistent use over several weeks, as your body adjusts to this combination diabetes medication and your healthcare provider fine-tunes the dosing regimen.

When should I take Volibo R 0.3/1mg and how should I use it properly?

Take Volibo R 0.3/1mg immediately before meals, ideally within 15 minutes of eating. This antidiabetic combination works best when synchronized with food intake, as repaglinide stimulates insulin release in response to carbohydrate consumption while voglibose slows glucose absorption. Swallow the tablet whole with water—do not crush or chew it. If you skip a meal, skip that dose to avoid hypoglycemia. Take it two to three times daily depending on your meal pattern and physician's instructions. Maintain consistent meal timing for optimal blood sugar control. Always follow your doctor's prescribed dosage and never adjust without medical guidance.

Is Volibo R 0.3/1mg safe for long-term diabetes management?

Volibo R 0.3/1mg is generally considered safe for extended use in type 2 diabetes management when prescribed and monitored appropriately by healthcare professionals. Clinical studies support the long-term efficacy and safety profile of both voglibose and repaglinide in combination therapy. Your physician will schedule regular blood glucose monitoring, HbA1c testing, and liver function assessments to ensure the medication continues working effectively without adverse effects. Long-term users should maintain consistent dosing schedules, adhere to dietary recommendations, and report any unusual symptoms promptly. Most patients tolerate this dual-action diabetes medicine well over extended periods with proper medical supervision and lifestyle modifications.

Can I take Volibo R 0.3/1mg alongside other medications?

Volibo R 0.3/1mg may interact with various medications, requiring careful management. Beta-blockers, corticosteroids, and certain antibiotics can alter blood glucose levels or affect how this diabetes medication works. Other antidiabetic drugs may increase hypoglycemia risk when combined with this voglibose-repaglinide combination. Drugs metabolized by CYP3A4 enzymes can influence repaglinide levels in your bloodstream. Always inform your physician and pharmacist about all prescription medicines, over-the-counter products, supplements, and herbal remedies you're taking. Your doctor will assess potential interactions and adjust dosages accordingly to maintain safe, effective diabetes control without compromising your overall treatment plan.

How does Volibo R 0.3/1mg compare to other diabetes combination medications?

Volibo R 0.3/1mg offers distinct advantages compared to other combination diabetes therapies. Unlike metformin-based combinations that may cause gastrointestinal distress, this voglibose-repaglinide pairing typically produces fewer digestive side effects. Compared to sulfonylureas, repaglinide provides shorter-acting insulin stimulation with lower all-day hypoglycemia risk. The alpha-glucosidase inhibitor voglibose specifically targets post-meal glucose spikes, complementing repaglinide's mealtime insulin response. This dual mechanism addresses multiple aspects of glycemic dysregulation simultaneously. While DPP-4 inhibitors and SGLT2 inhibitors offer alternative approaches, Volibo R remains particularly effective for patients requiring robust postprandial glucose control with rapid-acting mealtime insulin secretion support.

Is generic voglibose/repaglinide as effective as branded Volibo R?

Generic voglibose and repaglinide combinations are therapeutically equivalent to branded Volibo R 0.3/1mg when manufactured to proper pharmaceutical standards. Regulatory authorities require generic diabetes medications to demonstrate bioequivalence, meaning they deliver the same active ingredients at identical concentrations with comparable absorption rates. Both generic and branded versions must meet strict quality control standards for purity, potency, and stability. The primary differences lie in inactive ingredients, packaging, and cost rather than clinical effectiveness. Many patients successfully manage type 2 diabetes with quality generic alternatives at significantly lower prices. Ensure you purchase from licensed pharmacies that source authentic medications to guarantee therapeutic efficacy and safety.

Why do patients choose PremiumRxDrugs for their Volibo R 0.3/1mg prescriptions?

Patients consistently choose PremiumRxDrugs for Volibo R 0.3/1mg because of significant cost savings on this essential diabetes medication without compromising quality or authenticity. The pharmacy's licensing credentials and manufacturer-direct sourcing guarantee genuine voglibose-repaglinide tablets every time. Convenient features like simplified reordering and prescription tracking make long-term diabetes management easier. Discreet, secure packaging protects patient privacy while reliable international shipping ensures consistent medication access across the USA, UK, Australia, and Canada. Free shipping options further reduce treatment costs. With more than ten years serving the global diabetes community, PremiumRxDrugs combines affordability, authenticity, convenience, and trusted pharmaceutical expertise in one accessible platform.

What are the common side effects of voglibose and repaglinide combination therapy?

Common side effects of voglibose and repaglinide include gastrointestinal symptoms such as flatulence, abdominal discomfort, bloating, and diarrhea, primarily from voglibose's carbohydrate-slowing action. Hypoglycemia (low blood sugar) may occur, especially if meals are skipped after taking repaglinide, causing shakiness, sweating, confusion, or dizziness. Some patients experience mild nausea or headaches initially. Weight gain can occur as improved glucose control enhances nutrient absorption. Digestive symptoms typically diminish as your body adapts to this antidiabetic combination. Serious side effects like severe hypoglycemia, allergic reactions, or liver function changes are rare but require immediate medical attention. Most people tolerate this diabetes medication well with proper meal timing.

Who should not take voglibose and repaglinide for diabetes management?

Voglibose and repaglinide are contraindicated for individuals with type 1 diabetes, diabetic ketoacidosis, or severe kidney impairment, as these conditions require different treatment approaches. Patients with significant liver dysfunction should avoid this combination due to repaglinide metabolism concerns. Those with inflammatory bowel disease, intestinal obstruction, or severe digestive disorders may not tolerate voglibose well. Pregnant or breastfeeding women should not use this antidiabetic combination without explicit medical guidance. People with known hypersensitivity to either active ingredient must choose alternative diabetes medications. Children and adolescents typically aren't prescribed this therapy, as safety data in pediatric populations remains limited. Your healthcare provider will evaluate your complete medical history before prescribing.

SKU	2608
Generic For	Voglibose R
Manufacturer	Ajanta Pharma India
Active Ingredient	Voglibose / Repaglinide

Volibo R 0.3/1 mg